Company intelligence / Profile preview

3Bar Biologics

Ownership: Private
Development stage: Commercial

Overview

The company has demonstrated that its patented system can deliver fresh, viable microbes to farmers at the time of application, improving crop yields and reducing reliance on synthetic chemicals. Their first product VIAH A1 is approved for organic production. They have won industry awards for innovation. No clinical results in the medical sense.

Therapeutic areas: Other
Modalities: Microbial therapyLive biotherapeutic product therapy
Industry: Agriculture & AgTech

Drug pipeline

2 assets

Bio-YIELD

Commercial

Indications: Crop yield improvement

1 more asset in the full pipeline.

Request access →

Partnerships

Partnering with discovery companiesdistributorsbulk suppliersresearch universities including The Ohio State University

Beyond the preview

Go deeper on 3Bar Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3Bar Biologics.

Explore the full profile